Daily Stock Analysis, ESPR, Esperion Therapeutics Inc, priceseries

Esperion Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
50.40
Close
51.03
High
51.60
Low
49.87
Previous Close
50.96
Daily Price Gain
0.07
YTD High
76.98
YTD High Date
Feb 13, 2020
YTD Low
24.82
YTD Low Date
Mar 16, 2020
YTD Price Change
-10.31
YTD Gain
-16.81%
52 Week High
76.98
52 Week High Date
Feb 13, 2020
52 Week Low
24.82
52 Week Low Date
Mar 16, 2020
52 Week Price Change
4.50
52 Week Gain
9.67%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 31. 2017
12.12
Mar 16. 2017
29.45
31 Trading Days
143.03%
Link
LONG
Mar 20. 2017
41.22
Mar 21. 2017
44.72
1 Trading Days
8.48%
Link
LONG
Jun 21. 2017
41.02
Jul 19. 2017
46.00
19 Trading Days
12.13%
Link
LONG
Nov 20. 2017
53.16
Dec 5. 2017
58.70
10 Trading Days
10.43%
Link
LONG
Feb 13. 2018
69.99
Mar 1. 2018
77.54
11 Trading Days
10.79%
Link
LONG
Oct 31. 2018
45.43
Nov 12. 2018
52.07
8 Trading Days
14.61%
Link
LONG
May 3. 2019
43.24
May 29. 2019
49.97
17 Trading Days
15.55%
Link
LONG
Nov 15. 2019
40.47
Dec 5. 2019
48.73
13 Trading Days
20.40%
Link
LONG
Dec 18. 2019
52.68
Jan 10. 2020
59.63
15 Trading Days
13.20%
Link
LONG
Feb 7. 2020
61.74
Feb 21. 2020
65.88
9 Trading Days
6.71%
Link
LONG
Apr 16. 2020
35.86
Apr 30. 2020
39.61
10 Trading Days
10.46%
Link
LONG
May 5. 2020
40.54
May 14. 2020
44.94
7 Trading Days
10.86%
Link
Company Information
Stock Symbol
ESPR
Exchange
NasdaqGM
Company URL
http://www.esperion.com
Company Phone
734-887-3903
CEO
Tim M. Mayleben
Headquarters
Michigan
Business Address
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI 48108
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001434868
About

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The company was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.

Description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.